Show simple item record

dc.contributor.authorSow, Samba O.
dc.contributor.authorTapia, Milagritos D.
dc.contributor.authorChen, Wilbur H.
dc.descriptionAdditional authors: Haidara, Fadima C.; Kotloff, Karen L.; Pasetti, Marcela F.; Blackwelder, William C.; Traore, Awa; Tamboura, Boubou; Doumbia, Moussa; Diallo, Fatoumata; Coulibaly, Flanon; Onwuchekwa, Uma; Kodio, Mamoudou; Tennant, Sharon M.; Reymann, Mardi; Lam, Diana F.; Gurwith, Marc; Lock, Michael; Yonker, Thomas; Smith, Jonathan; Simon, Jakub K.; and Levine, Michael M.en_US
dc.description.abstractReactive immunization with a single-dose cholera vaccine that could rapidly (within days) protect immunologically-naïve individuals during “virgin soil” epidemics would facilitate cholera control. One dose of attenuated Vibrio cholerae O1 classical Inaba vaccine CVD 103-HgR (VaxchoraTM) containing >2x108 colony forming units (cfu) induces vibriocidal antibody seroconversion (correlate of protection) in >90% of U.S. adults. A previous CVD 103-HgR commercial formulation required >2x109 cfu to elicit high seroconversion in developing country populations. We compared vibriocidal responses of Malians (18-45 years old) randomized to ingest a single >2x108 cfu standard-dose (N=50) or >2x109 cfu high-dose (N=50) of PaxVax CVD 103-HgR with buffer, or two doses (N=50) of ShancholTM inactivated cholera vaccine (the immunologic comparator). To maintain blinding, participants were dosed twice, 2 weeks apart; CVD 103-HgR recipients ingested placebo weeks before or after ingesting vaccine. Seroconversion (>4-fold vibriocidal titer rise) between baseline and 14 days after CVD 103-HgR, and following the first and second dose of Shanchol were the main outcomes measured. By day 14 post-vaccination, seroconversion after a single standard-dose of CVD 103-HgR was 71.7% (33/46) and 83.3% (40/48) after high-dose. Seroconversion following first-dose Shanchol 56.0% (28/50) was significantly lower compared with high-dose CVD 103-HgR (p=0.003). High-dose CVD 103-HgR vibriocidal geometric mean titer (GMT) exceeded standard-dose GMT at day 14 (214 vs 95, p=0.045) and was ~2-fold higher than day 7 and day 14 GMT following the first Shanchol dose (p>0.05). High-dose CVD 103-HgR is recommended for accelerated evaluation in developing countries to assess efficacy and practicality in field situations. ( number, NCT02145377)en_US
dc.subjectlive oral vaccineen_US
dc.subjectreactive vaccinationen_US
dc.subjectsingle-dose vaccineen_US
dc.subject.meshCholera Vaccinesen_US
dc.titleA randomized, placebo-controlled, double-blind Phase 2 trial comparing the reactogenicity and immunogenicity of a single ≥2x108 colony forming units [cfu] standard-dose versus a ≥2x109 cfu high-dose of CVD 103-HgR live attenuated oral cholera vaccine, with Shanchol inactivated oral vaccine as an open label immunologic comparatoren_US
dc.title.alternativeHigh-dose vs standard-dose live oral cholera vaccineen_US

Files in this item

SowLiveOralCholeralVaccineOct2 ...
Microsoft Word 2007

This item appears in the following Collection(s)

Show simple item record
Except where otherwise noted, this item's license is described as